September 21, 2012
The Swedish pharmaceutical company Medivir AB announced a phase IIa combination trial of simeprevir (TMC435), a protease inhibitor, and TMC647055, a non-nucleoside inhibitor for treatment of chronic hepatitis C. At present, Simeprevir is in phase II clinical development and is being developed jointly by Medivir and Janssen Research & Development (R&D), Ireland. The non-nucleoside inhibitor TMC647055 is also developed by Janssen R&D. The trial will be an open label study of chronically- infected hepatitis C patients with HCV genotype-1a or 1b to determine the efficacy, safety, and tolerability of the combined drugs. The endpoint of the study is the patients' sustained virologic response 12 weeks after end of treatment (SVR12), that is the number of patients who will be virus free 12 weeks after the end of the combination drug treatment. Simeprevir, TMC647055, and low-dose ritonavir will be co-administered once daily with and without ribavirin for 12 weeks. The second part of the trial will test the same regimen in prior null responder patients chronically infected with HCV genotype 1a. For information about the study see www.clinicaltrials.gov.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|